Amiodarone-induced thyroid dysfunction

Journal of Intensive Care Medicine

Volumn 30, Issue 4, 2015, Pages 179-185

  Danzi, Sara ^a   Klein, Irwin ^b  

^a QUEENSBOROUGH COMMUNITY COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amiodarone induced thyrotoxicosis; heart; hyperthyroidism; hypothyroidism; T3; thyroid hormone; thyrotoxicosis; triiodothyronine

Indexed keywords

AMIODARONE; GLUCOCORTICOID; LEVOTHYROXINE; LIOTHYRONINE; PREDNISONE; THIAMAZOLE; THIONAMIDE; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROXINE; ANTIARRHYTHMIC AGENT;

GENE EXPRESSION; GOITER; HEART ARRHYTHMIA; HUMAN; HYPOTHYROIDISM; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; THYROID GLAND;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROID GLAND; THYROTOXICOSIS;

EID: 84930518013     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066613503278     Document Type: Review

References (61)

1. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999 ; 100 (19). 2025-2034
2. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007 ; 298 (11). 1312-1322
3. Al-Khatib SM, Allen LaPointe NM, Curtis LH, et al. Outpatient prescribing of antiarrhthmic drugs from 1995 to 2000. Am J Cardiol. 2003 ; 91 (1). 91-94
4. Bianco AC, Larsen PR. Cellular and structural biology of the deiodinases. Thyroid. 2005 ; 15 (8). 777-786
5. Amico JA, Richardson V, Alpert B, Klein I. Clinical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. 1984 ; 144 (3). 487-490
6. Klein I, Danzi S. The Thyroid: A fundamental and Clinical Text. 31, 10th Ed, Eds. BravermanL.UtigerR.. Philadelphia; Lippincott Williams & Wilkins: 2012. Braverman L. Utiger R., ed. Philadelphia: Lippincott Williams & Wilkins ; 2012 :
7. Klein I, Danzi S. The Thyroid: A Fundamental and Clinical Text. 53, 10th Ed, Eds BravermanL.UtigerR.. Philadelphia; Lippincott Williams & Wilkins: 2012. Braverman L. Utiger R., ed. Philadelphia: Lippincott Williams & Wilkins ; 2012 :
8. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007 ; 116 (15). 1725-1735
9. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012 ; 96 (2). 257-268
10. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005 ; 118 (7). 706-714
11. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997 ; 126 (1). 163-173
12. van Beeren HC, Kwakkel J, Ackermans MT, Wiersinga WM, Fliers E, Boelen A. Action of specific thyroid hormone receptor α(1) and β(1) antagonists in the central and peripheral regulation of thyroid hormone metabolism in the rat. Thyroid. 2012 ; 22 (12). 1275-1282
13. van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3′-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology. 1996 ; 137 (7). 2807-2814
14. van Beeren HC, Bakker O, Chatterjee VK, Wiersinga WM. Effect of mutations in the beta1-thyroid hormone receptor on the inhibition of T3 binding by desethylamiodarone. FEBS Lett. 1999 ; 450 (1-2). 35-38
15. Rao RH, McReady VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab. 1986 ; 62 (3). 563-567
16. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001 ; 22 (2). 240-254
17. Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. JCEM. 2012 ; 97 (2). 499-506
18. Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011 ; 75 (3). 388-394
19. Conen D, Melly L, Kaufmann C, et al. Amiodarone-induced thyrotoxicosis. JACC. 2007 ; 49 (24). 2350-2355
20. Daniels G. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2001 ; 86 (1). 3-8
21. Rosene ML, Wittmann G, Arrojo e Drigo R, et al. Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. Endocrinology. 2010 ; 151 (12). 5961-5970
22. Iervasi G, Clerico A, Bonini R, et al. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. J Clin Endocrinol Metab. 1997 ; 82 (1). 275-280
23. Coceanu M, Molinaro S, Scalese M, et al. Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction. J Endocrinol Invest. 2011 ; 34 (6). 144-148
24. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Amiodarone and thyroid function. Nat Rev Endocrinology. 2010 ; 6 (1). 34-41
25. Polikar R, Goy JJ, Schlapfer J, et al. Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes. Am J Cardiol. 1986 ; 58 (10). 987-991
26. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009 ; 23 (6). 735-751
27. Lafuente-Lafuente C, Alvarez J-C, Leenhardt A, et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol. 2009 ; 67 (5). 511-519
28. Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991 ; 91 (5). 507-511
29. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Brogioni S, Martino E. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. J Clin Endocrinol Metab. 2011 ; 96 (11). 3374-3380
30. Kurt IH, Yigit T, Karademir BM. Atrial fibrillation due to late amiodarone-induced thyrotoxicosis. Clin Drug Investig. 2008 ; 28 (8). 527-531
31. Stan MN, Hess EP, Bahn RS, et al. A risk prediction index for amiodarone-induced thyrotoxicosis in adults with congenital heart disease. J Thyroid Res. 2012 ;: 2012
32. Chute JP, Ryan CP, Sladek G, Shakir JM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism. Endocr Pract. 1997 ; 3 (2). 77-79
33. Pincus D, Gomes T, Hellings C, et al. A population based assessment of the drug interaction between lexothyroxine and warfarin. Clin Pharmacol Ther. 2012 ; 92 (6). 766-770
34. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996 ; 81 (8). 2930-2933
35. Bogazzi F, Bartalena L, Martino E. Approach to the patient with Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010 ; 95 (6). 2529-2535
36. Bogazzi F, Bartalena L, Gaasperi M, Braverman LE, Martino E. The various effects of amiodarone on thyroid function. Thyroid. 2001 ; 11 (5). 511-519
37. Piga M, Serra A, Boi F, Tanda ML, Martino E, Mariotti S. Amiodarone-induced thyrotoxicosis. a review. Minverva Endocrinol. 2008 ; 33 (3). 213-228
38. Bartalena L, Wiersinga WM, Tanda ML, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European thyroid association. Clin Endocrinol (Oxf). 2004 ; 61 (4). 494-502
39. Bartalena L, Brogioni S, Grasso L, et al. Interleukin-6: a marker of thyroid destructive processes?. J Clin Endocrinol Metab. 1994 ; 79 (5). 1424-1427
40. Tanda ML, Bogazzi F, Martino E, Bartalena L. Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?. Eur J Endocrinol. 2008 ; 159 (4). 359-361
41. Bartalena L, Bogazzi F, Martino E. Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin Endocrinol (Oxf). 2002 ; 56 (1). 23-24
42. Loy M, Perra E, Melis A, et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol. 2007 ; 48 (6). 628-634
43. Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2003 ; 26 (7). 635-640
44. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3 year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002 ; 56 (1). 33-38
45. Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid. 2002 ; 12 (6). 523-525
46. Farwell AP, Abend SL, Huang SK, Patwardhan NA, Braverman LE. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA. 1990 ; 263 (11). 1526-1528
47. Klein I, Danzi S. Evaluation of the therapeutic efficacy of different l-thyroxine preparations in the treatment of human thyroid disease. Thyroid. 2003 ; 13 (12). 1127-1132
48. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. 2002 ; 105 (11). 1275-1277
49. Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003 ; 88 (5). 1999-2002
50. Franklyn JA, Gammage MD. Treatment of amiodarone-associated thyrotoxicosis. Nat Clin Pract Endocrinol Metab. 2007 ; 3 (9). 662-666
51. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009 ; 25 (7). 421-424
52. Vanderpump MP. Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis. Nat Rev Endocrinol. 2009 ; 5 (12). 650-651
53. Bogazzi F, Tomisti L, Rossi G, et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab. 2009 ; 94 (10). 3757-3762
54. Yiu KH, Jim MH, Siu CW, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009 ; 94 (1). 109-114
55. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodine-induced hypothyroidism. Thyroid. 2001 ; 11 (5). 501-510
56. Mosher MC. Amiodarone-induced hypothyroidism and other adverse effects. Dimens Crit Care Nurs. 2011 ; 30 (2). 87-93
57. Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006 ; 331 (3). 154-156
58. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association. Endocr Pract. 2012 ; 18 (6). 988-1028
59. Beyer IW, Karmali R, Demeester-Mirkine N, Cogan E, Fuss MJ. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid. 1998 ; 8 (11). 1029-1031
60. Klein I, Parker M, Mantel P, Levey GS. Resolution of abnormal muscle enzyme studies in hypothyroidism. Am J Med Sci. 1980 ; 279 (3). 159-162
61. Rush J, Danzi S, Klein I. Role of thyroid disease in the development of statin-induced myopathy. Endocrinologist. 2006 ; 16 (5). 279-285